Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:drug |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2024
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:B01AX
|
| gptkbp:brand |
Winrevair
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developer |
gptkb:Merck_&_Co.
gptkb:Acceleron_Pharma |
| https://www.w3.org/2000/01/rdf-schema#label |
sotatercept
|
| gptkbp:indication |
treatment of adults with pulmonary arterial hypertension
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:protein
|
| gptkbp:mechanismOfAction |
activin signaling inhibitor
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
diarrhea
dizziness fatigue headache hypertension epistaxis nasopharyngitis |
| gptkbp:target |
activin receptor type IIA-Fc fusion protein
|
| gptkbp:usedFor |
pulmonary arterial hypertension
|
| gptkbp:bfsParent |
gptkb:Acceleron_Pharma
|
| gptkbp:bfsLayer |
5
|